Sandoz, Boehringer’s Interchangeable US Humira Biosimilars Land Preferred Status
PBM Optum Rx To Offer Spaces, Having Given One To First Mover Amgen
As the clock ticks on the second wave of biosimilar Humira launches in the US, Sandoz and Boehringer Ingelheim have scooped much-coveted preferred listings on the commercial formulary of a major PBM for their biosimilars, following Amgen’s placement earlier this year.
